“Lung cancer stem cells appear to be the major drivers in many common lung cancers, and in order for a therapeutic treatment to be effective, it has to disrupt these cancer stem cells,” said Dr. Alan Fields, the study’s senior author and chair of the Department of Cancer Biology at Mayo Clinic Florida. “We show that aurothiomalate, the agent now being tested in lung cancer patients, can, in fact, target these cells.”
The study was funded by grants from the National Cancer Institute, the V-Foundation and the American Lung Association/LUNGevity. Other Mayo Clinic researchers who participated in the study were Dr. Roderick Regala, Dr. Rebecca Davis, Alyssa Kunz, and Dr. Andras Khoor. Also collaborating on the study was Michael Leitges of the University of Oslo.
1 comment:
Hi, it's a very great blog.
I could tell how much efforts you've taken on it.
Keep doing!
Post a Comment